Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Clinical trial NCT05714683 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05714683
- Sponsor
- Novo Nordisk A/S
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-12-31
- Primary completion
- 2026-10-30
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.